RASSF1A is a tumor suppressor gene on 3p21.3 frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma (NPC). To identify RASSF1A target genes in NPC, we have investigated the expression profile of the stable RASSF1A transfectants and controls by high-density oligonucleotide array. A total of 57 genes showed differential expression in the RASSF1A-expressing cells. These RASSF1A target genes were involved in multiple cellular regulatory processes such as transcription, signal transduction, cell adhesion and RNA processing. The RASSF1A-modulated expression of eight selected genes with the highest fold changes (ATF5, TCRB, RGS1, activin bE, HNRPH1, HNRPD, Id2 and CKS2) by RASSF1A was confirmed in both stable and transient transfectants. Compared with the RASSF1A transfectants, an inverse expression pattern of activin bE, Id2 and ATF5 was shown in the immortalized nasopharyngeal epithelial cells treated with siRNA against RASSF1A. The findings imply that the expression of activin bE, Id2 and ATF5 was tightly regulated by RASSF1A and may associate with its tumor suppressor function. Strikingly, overexpression of Id2 is common in NPC and RASSF1A-induced repression of Id2 was mediated by the overexpression of activin bE. The results suggest a novel RASSF1A pathway in which both activin bE and Id2 are involved.
Allelic loss of chromosome 3p is the most common genetic change reported in nasopharyngeal carcinoma (NPC) . Almost all primary NPC and a majority of the precancerous lesions showed loss of heterozygosity (LOH) on chromosome 3p, suggesting that inactivation of tumor suppressor gene(s) at this chromosomal region is early and critical in the development of NPC . Although multiple NPC-related tumor suppressor loci were deduced from LOH studies, 3p21.3 was the most promising target based on the functional evidence that microcell hybrids of 3p21.3 with an NPC cell line displayed tumor suppressor activity (Cheng et al., 1998; Lo et al., 2000; . This NPC-specific tumor suppressor locus was resided within an 11.2-cM region bounded by D3S1298 and D3S1578 (Cheng et al., 1998) . In our previous study, we have shown that the RASSF1A tumor suppressor, which is located in this region, was frequently inactivated in NPC by either genetic or epigenetic alterations Kwong et al., 2002) . Ectopic expression of RASSF1A has also been shown to reduce colony formation in vitro and suppressed tumorigenicity in vivo in various cancer cell lines including NPC (Dammann et al., 2000; Burbee et al., 2001; Shivakumar et al., 2002; Chow et al., 2004) . All these findings imply that RASSF1A is an important tumor suppressor gene in this cancer.
RASSF1A belongs to a family of proteins characterized by the presence of the Ras-association (RA) domain at the C-terminus. Although RASSF1A showed high sequence homology to another Ras effector, Nore1, it was unable to bind to Ras directly. Instead, RASSF1A forms homodimers or heterodimers with Nore1 (Ortiz-Vega et al., 2002) . Both RASSF1A and human NORE1 interact with the proapoptotic kinase MST1 and led to apoptosis upon serum stimulation or Ras activation . Aside from apoptosis, RASSF1A was found to be involved in cell cycle regulation. RASSF1A-induced G0/G1 arrest in lung cancer cell lines and cyclin D1 downregulation was observed in lung and neuroblastoma cell lines (Shivakumar et al., 2002; Agathanggelou et al., 2003) . RASSF1A was shown to localize with microtubule and important in maintaining microtubule stability recently (Liu et al., 2003) . It regulates the stability of mitotic cyclins and the timing mitotic progression through the inhibition of APC-Cdc20 complex (Song et al., 2004) . RASSF1A-depleted cells displayed accelerated mitotic progression and various mitotic abnormalities. RASS-F1A has also been shown to interact with the E1A-regulated transcription factor p120E4F and the scaffold protein CNK1 (Fenton et al., 2004; Rabizadeh et al., 2004) . Tommasi et al. (2005) has further demonstrated increased tumor susceptibility in Rassf1a knockout mice. Using cDNA microarray, transcriptional target genes of RASSF1A in NSCLC and neuroblastoma have been explored. From the proposed functions of the gene expression targets, RASSF1A may be involved in various critical cellular pathways in these two cancer types (Agathanggelou et al., 2003) .
In the present study, we explored the roles of RASSF1A in NPC by identifying novel RASSF1A-regulated genes. In order to identify genes modulated by RASSF1A in NPC, the expression profile of RASSF1A-expressing NPC cells and controls were investigated. High-density oligonucleotide microarray was performed on two well-characterized RASSF1A-expressing C666-1 clones, #20 and #22 (Chow et al., 2004) . The two stable RASSF1A-transfected clones demonstrated retarded cell proliferation in vitro. Soft-agar assay also showed decreased number and sizes of colony formed in these clones. In vivo nude mice assay demonstrated the dramatic reduction of tumorigenic potential in the RASSF1A-transfected clones (Chow et al., 2004 ). The mean gene expression level of the clones was compared to the parental C666-1 cells and vector-transfected clones. Consistent change of gene expression between transfected clones and control cells with a minimum of two-fold and Po0.001 was scored as significant. Using these stringent selection criteria, we identified 57 differentially expressed genes in the microarray analysis (Table 1) . Totally, 30 genes were downregulated whereas 27 were upregulated. These genes fall into several functional categories such as transcription (e.g. ATF5, DDIT3, ATF3), signal transduction (e.g. RGS1, INHBE/activin bE, PLAB), cell adhesion (e.g. LMNB1, LGALS1, TROAP) and RNA processing (e.g. HNRPA1, HNRPH1).
Comparing the findings from the previous microarray study of RASSF1A-transfected NSCLC cells A549 with the current study, distinct groups of RASSF1A target genes in these two tumor types was revealed (Agathanggelou et al., 2003) . Nevertheless, the results are in concordance with the different phenotypic changes of RASSF1A transfected NPC (C666-1) and NSCLC (A549) cells. Overexpression of RASSF1A in A549 cells led to G0/G1 cell cycle arrest, however, such observation was not detected in C666-1 (Agathanggelou et al., 2003; Chow et al., 2004) . This implies that RASSF1A-induced tumor suppressor function may be mediated through diverse cell signaling pathways in different cell lineages. Although the RASSF1A target genes in the two cell types are varied, nevertheless, more than 15% of the identified target genes in both cell types were involved in transcription and signal transduction. This suggests that RASSF1A probably function as a transcription regulator or signaling molecule.
Among the RASSF1A target genes identified by microarray analysis, 13 known genes with the highest fold changes were selected for verification by quantitative reverse-transcription polymerase chain reaction (QRT-PCR) and Western blotting. These genes include nine upregulated genes (ATF5, TCRB, RGS1, TRIB3, ASS, WARS, activin bE/INHBE, PLAB, SH3BGR) and four downregulated genes (HNRPH1, HNRPD, Id2 and CKS2). The results of QRT-PCR were shown in Figure 1a . Comparing the findings from microarray analysis with that of QRT-PCR revealed remarkable correlation ( Figure 1a ). The transcriptional changes of these 13 target genes were further analysed from C666-1 cells transiently transfected with pcDNA3.1 þ /RASS-F1A. The expression changes of eight genes (RGS1, ATF5, activin bE/INHBE, TCRB, HNRPH1, HNRPD, Id2 and CKS2) in the transiently transfected C666-1 cells were in consistent with that of the stable clones ( Figure 1b) . The findings confirmed that transcriptional regulation of these eight genes in NPC cells by RASSF1A was not due to the clonal effect of individual transfected clones. We have also shown the expression changes of RGS1 and Id2 at protein level where the antibodies are available. By Western blotting, the ectopic expression of RASSF1A in the stable transfectants (#20 and #22) resulted in induction of RGS1 protein expression. In contrast, Id2 expression was repressed in the two clones ( Figure 1c ). From transient transfection assay, induction of RASSF1A was observed after 4 h of transfection and expression was peaked at 24 h. RGS1 expression was increased slightly at 4 h post-transfection. Moreover, Id2 expression was dropped drastically in response to RASSF1A overexpression, with the lowest protein expression at 48 h post-transfection (Figure 1d ).
To further investigate the effect of inhibiting endogenous RASSF1A on these RASSF1A-modulated genes, small interfering RNA (siRNA) targeting RASSF1A was transfected into an immortalized nasopharyngeal epithelial cell line, NP69 (Tsao et al., 2002) . As demonstrated in Figure 2a , treatment of siRNA for 48 h led to drastic downregulation of RASSF1A transcript (80%, Figure 2a) . Reduction of RASSF1A protein expression was also shown in the NP69 treated with siRNA against RASSF1A (Figure 2b ). By QRT-PCR, we found no significant changes of expression of the HNRPH1 and HNRPD genes in the siRNA-treated NP69 cells. Although the TCRB gene was upregulated by restoring RASSF1A expression in NPC cells, no reduction of TCRB expression was detected in the RASSF1A siRNA-treated immortalized NP cells. Depletion of endogenous RASSF1A expression showed repression of activin bE and ATF5, which were upregulated in NPC cells as a result of RASSF1A expression (Figure 2a) . Moreover, upregulation of Id2 expression was elevated with RASSF1A depletion. These findings suggest that these three target genes are tightly regulated by RASSF1A. However, we were not able to investigate the expression of RGS1 in NP69 since we found no RGS1 transcripts in this cell line. Nevertheless, RGS1 mRNA was expressed in normal nasopharyngeal epithelial samples (data not shown).
The functions of these RASSF1A downstream targets appeared important in transformation. Activating transcription factor 5 (ATF5) is a member of the ATF/CREB family of bZIP transcription factors. These RASSF1A modulated genes in NPC LS-N Chow et al High-density oligonucleotide microarray was performed on the parental C666-1 cells, vector-transfected clones and two RASSF1A-expressing C666-1 clones, #20 and #22 (Chow et al., 2004) . Cells were harvested at 50-70% confluency and total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA, USA). In total, 10 mg of RNA was subjected to double-stranded cDNA synthesis and in vitro transcription according to the manufacturer's recommendation (Affymetrix, Santa Clara, CA, USA). The purified biotinylated cRNA transcripts was chemically fragmented and hybridized to the U133A arrays, according to the manufacturer's instructions. The Genechip Fluidics Station 400 (Affymetrix) was used for washing and staining of the Human U133A arrays. Arrays were scanned by the GeneChip GeneArray Scanner (Affymetrix). The raw image DAT data files were processed using Affymetrix MAS 5.0. Normalization of arrays and model-based analysis of oligonucleotide arrays were performed using dChip (http://www.dchip.org/). Genes whose signals were increased (I) or decreased (D) by more than two-fold with Po0.001 in both #20 and #22 clones were scored as significant (Kang et al., 2003) . Molecular functions of the genes were classified according to The Cancer Genome Anatomy Project (http://cgap.nci.nih.gov/). QRT-PCR analysis of 13 selected RASSF1A target genes identified by microarray analysis. QRT-PCR was carried out essentially the same as described (Chow et al., 2004) . The relative expression level was calculated by the 2 ÀDDCT method. Each experiment was carried out in triplicate. (b) Expression of RASSF1A-modulated genes in C666-1 transiently transfected with RASSF1A. The plasmids pcDNA3.1 þ /RASSF1A and pcDNA3.1 þ were described previously (Chow et al., 2004) . Cells (5 Â 10 5 ) were seeded in a 60-mm dish 48 h before transfection. In total, 10 mg of plasmid DNA was transfected into C666-1 using Lipofectamine 2000 (Invitrogen) and transfected cells were harvested at specific time point. (c) RGS1 and Id2 protein expression in RASSF1A-transfected stable clones (#20 and #22). (d) RGS1 and Id2 protein expression in RASSF1A transient transfection assay. Western blot analysis was performed as described previously (Chow et al., 2004) . The primary antibodies used were goat anti-human actin (I-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-human Id2 (Zymed, South San Francisco, CA, USA) and mouse anti-human RASSF1A (eB114, eBioscience, San Diego, CA, USA). RGS1 antibody was obtained from the Center for Biomedical Inventions, The University of Texas, Southwestern at Dallas. HRP-conjugated secondary antibodies were purchased from DAKO (Glostrup, Denmark).
RASSF1A modulated genes in NPC LS-N Chow et al transcription factors play a key role in regulating cell growth, proliferation and programmed cell death. A handful of evidence from mouse has suggested an antiapoptotic role of ATF5 (Persengiev et al., 2002) . More recently, human ATF5 was found to be associated with Cyclin D3 and such an interaction potentiated the transcriptional activity of ATF5 (Liu et al., 2004) . RGS1 is one of the member of regulator of G-protein signaling (RGS) proteins, which are implicated in the fine-tuning of various cellular events in response to G-protein coupled receptor activation. Previous studies have shown that RGS1 was able to attenuate activation of MAPK and ERK (Zhang et al., 1999) . It is possible that RASSF1A involved in the tuning of G-protein signaling through the modulation of RGS1.
Among the RASSF1A-modulated genes, both activin bE and Id2 were found to be involved in transforming growth factor beta (TGFb) signaling pathway and tumorigenesis of various cancers. Regulation of activin bE, the TGFb superfamily of growth factors, by RASSF1A suggests the involvement of TGFb signaling pathway in the tumor suppressor function of RASS-F1A. In previous studies, expression of activin bE was dramatically downregulated in human and rat liver cancer cell lines. Overexpression of activin bE in mouse liver inhibited regenerative DNA synthesis (Chabicovsky et al., 2003) . Furthermore, ectopic expression of activin bE in hepatoma cell lines resulted in apoptosis (Vejda et al., 2003) . These findings implied that activin bE is an important factor for growth suppression. Additionally, Id2, a downstream target of TGFb signaling pathway, was also transcriptionally regulated by RASSF1A. The Id proteins have been recognized as positive regulators of cell proliferation, oncogenesis and invasion; deregulated expression of Id2 mRNA and proteins has also been detected in various cancers such as mammary gland, pancreatic and colorectal cancers (Coppe et al., 2003) . The association of Id2 with Rb and myc further supports its role in transformation and tumorigenesis.
Although TGFb is a well-documented transcription repressor of Id2, the relationship between activins and Id2 is unclear. Our findings showed that RASSF1A induced activin bE and repressed Id2 in C666-1 cells (Figure 1a and b) . Based on this result, we hypothesized that RASSF1A may repress Id2 expression through the modulation of activin bE in NPC. Thus, we have investigated the expression of Id2 in C666-1 cells transfected with full-length activin bE. As shown in Figure 3a , overexpression of activin bE in C666-1 cells led to reduced expression of Id2, compared to the vector control 24 h after transfection (Figure 3a) . The result implies that activin bE is able to repress Id2 expression in NPC cells. We have further examined the status of activin bE and Id2 in NPC samples. Downregulation of RASSF1A and activin bE, together with overexpression of Id2, were commonly found in NPC cell lines and xenografts (Figure 3b) . By immunohistochemical staining, we detected overexpression of Id2 in 93.3% (42/45) of primary NPC and representative examples were shown in Figure 3c . We also examined RASSF1A methylation by methylation-specific PCR (MSP) on 33 cases where genomic DNA was available. Our results showed concurrent overexpression of Id2 and methylation of RASSF1A in 57.6% (19/33) of NPC specimen. The findings indicated overexpression of Id2 and downregulation of activin bE, as well as inactivation of RASSF1A, may be the critical events associated with NPC tumorigenesis.
In summary, expression profiling of RASSF1A-transfected NPC cells identified a number of novel RASSF1A target genes that may be important in the tumorigenesis of NPC. In this study, we first demonstrated that a RASSF1A/activin bE/Id2 pathway in which RASSF1A-induced Id2 repression was mediated through overexpression of activin bE (Figure 3d ). The present study shed light to the precise mechanism of RASSF1A-induced tumor inhibition and further strengthens its role as a major tumor suppressor within 3p21.3 in NPC. (Shivakumar et al., 2002) . For siRNA transfection, duplex siRNA (100 nM) was transfected into NP69 at 30% confluency using Lipofectamine 2000. Cells were harvested for RNA or protein extraction 48 h after siRNA transfection. Three RASSF1A target genes (activin bE, Id2 and ATF5) showed an inverse expression pattern compared to RASSF1A-transfected cells. (b) Reduction of RASSF1A protein expression after siRNA treatment in NP69.
